Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.
The price of Moderna Inc (NASDAQ: MRNA) closed at $32.99 in the last session, up 3.35% from day before closing price of $31.92. In other words, the price has increased by $3.35 from its previous closing price. On the day, 25.29 million shares were traded. MRNA stock price reached its highest trading level at $33.91 during the session, while it also had its lowest trading level at $29.2543.
Ratios:
We take a closer look at MRNA’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 3.62 and its Current Ratio is at 3.67. In the meantime, Its Debt-to-Equity ratio is 0.07 whereas as Long-Term Debt/Eq ratio is at 0.07.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Goldman on January 29, 2025, Downgraded its rating to Neutral and sets its target price to $51 from $99 previously.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Dec 09 ’24 when Klinger Shannon Thyme sold 529 shares for $44.68 per share. The transaction valued at 23,637 led to the insider holds 20,446 shares of the business.
Klinger Shannon Thyme bought 529 shares of MRNA for $23,637 on Dec 09 ’24. On Dec 03 ’24, another insider, Klinger Shannon Thyme, who serves as the Chief Legal Officer of the company, sold 112 shares for $43.30 each. As a result, the insider received 4,849 and left with 19,837 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, MRNA now has a Market Capitalization of 12695145472 and an Enterprise Value of 6386149888. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.92 while its Price-to-Book (P/B) ratio in mrq is 1.06. Its current Enterprise Value per Revenue stands at 1.973 whereas that against EBITDA is -1.7.
Stock Price History:
The Beta on a monthly basis for MRNA is 1.83, which has changed by -0.62076104 over the last 52 weeks, in comparison to a change of 0.22894537 over the same period for the S&P500. Over the past 52 weeks, MRNA has reached a high of $170.47, while it has fallen to a 52-week low of $30.24. The 50-Day Moving Average of the stock is -15.65%, while the 200-Day Moving Average is calculated to be -58.30%.
Shares Statistics:
According to the various share statistics, MRNA traded on average about 10.61M shares per day over the past 3-months and 13377870 shares per day over the past 10 days. A total of 384.82M shares are outstanding, with a floating share count of 343.14M. Insiders hold about 10.83% of the company’s shares, while institutions hold 70.88% stake in the company. Shares short for MRNA as of 1738281600 were 40600489 with a Short Ratio of 3.83, compared to 1735603200 on 37847737. Therefore, it implies a Short% of Shares Outstanding of 40600489 and a Short% of Float of 13.88.
